Answers are grounded in this paper and cite their sources.
BACKGROUND: New prognostic factors have been reported in patients with metastatic or recurrent gastric cancer (MRGC), necessitating modifications to the previous prognostic model. AIM: To develop a new model, MRGC patients who received fluoropyrimidines/ platinum doublet chemotherapy between 2008 and 2015 were analyzed. METHODS: = 946). CONCLUSION: We identified six factors readily measured in clinical practice that are predictive of poor prognosis in patients with MRGC. The new model is simpler than the old and more easily predicts OS.
No takes yet. Share an insight, caveat, or question.
Koo et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: